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Aims. The aim of this study was to evaluate the eﬀect of acute glycemia increase on microvasculature and endothelium in Type 1
diabetes during hyperinsulinemic clamp. Patients and Methods. Sixteen patients (51±7yrs) without complications were examined
during iso- and hyperglycemic clamp (glucose increase 5.5mmol·L−1). Insulin, lipid parameters, cell adhesion molecules and
ﬁbrinogenwereanalyzed.Microvascularreactivity(MVR)wasmeasuredbylaserDopplerﬂowmetry.Results.Maximumperfusion
andthevelocityofperfusionincreaseduringPORHwerehigherinhyperglycemiacomparedtobaseline(47±16versus40±16PU,
P<0.01, and 10.4 ± 16.5v e r s u s2 .6 ± 1.5PU·s−1, P<0.05, resp.). Time to the maximum perfusion during TH was shorter and
velocityofperfusionincreaseduringTHhigherathyperglycemiacomparedtoisoglycemicphase(69±15versus77±16s,P<0.05,
and 1.4 ± 0.8v e r s u s1 .2 ± 0.7PU·s−1, P<0.05, resp.). An inverse relationship was found between insulinemia and the time to
maximum perfusion during PORH (r =− 0.70, P = 0.007). Conclusion. Acute glycemia did not impair microvascular reactivity
in this clamp study in Type 1 diabetic patients. Our results suggest that insulin may play a signiﬁcant role in the regulation of
microvascular perfusion in patients with Type 1 diabetes through its vasodilation eﬀect and can counteract the eﬀect of acute
glucose ﬂuctuations.
1.Introduction
Hyperglycemia is an independent risk factor for the develop-
ment of vascular complications in patients with diabetes. It
has multiple negative eﬀects on vessel wall, and maintaining
good glycemic control signiﬁcantly reduces the risk of both
microvascular and macrovascular complications in diabetic
patients [1–4]. Short-term glycemic variability is also dis-
cussed as a potential additional independent risk factor
for the development of diabetic complications. Increased
glycemic variability may contribute to the risk of micro-
and macrovascular complications in patients with Type 2
diabetes [5–8]. One solitary study on a smaller number of
Type 1 diabetic patients indicates a possible connection be-
tween increased glycemic variability and the development
of diabetic neuropathy [9]. However, based on the analyses
of data from DCCT study, it was reported that increased
glycemic variability is not an additional factor contributing
to the risk of microvascular complications in Type 1 diabetic
patients [10, 11]. As the data regarding the eﬀect of increased
glycemic variability on diabetic complications are limited,
the importance of glycemic variability in Type 1 diabetes is
not yet clear.
It is also not quite clear how increased glycemic varia-
bility could induce diabetic complications. Oxidative stress
was suggested as a possible common mechanism of the
endothelial impairment induced by increased glycemic vari-
ability [12–16]. Endothelial dysfunction, a ﬁrst event in
the process of vascular impairment, can be induced by
increased oxidative stress. It has been shown in experimental
studies in Type 2 diabetic patients that both single and
multipleglycemiaincreaseinduceoxidativestressandimpair2 Experimental Diabetes Research
endothelial function [17, 18]. Again, especially in Type 1 dia-
betic patients, the data on the eﬀects of acute hyperglycemia
on vascular function are limited.
InType2diabetes,hyperglycemiaisoftenassociatedwith
hyperinsulinemia (depending on the stage of diabetes), dys-
lipidemia, arterial hypertension, and other metabolic abnor-
malities that may modify the impact of acute hyperglycemia
on vascular function [19, 20]. Although the metabolic
disorderstypicallyassociatedwithType2diabetesareusually
not present in Type 1 diabetes, insulin alters the vascular
function in Type 1 diabetes as well [21]. Both hyperglycemia
and hyperinsulinemia can aﬀect vascular reactivity [21, 22],
and it is even not clear whether some abnormalities in
vascular function cannot be attributed to hyperinsulinemia
rather than to hyperglycemia [23].
It has been shown either in vitro or in vivo that insulin
exerts an anti-inﬂammatory and/or antiprooxidant action
[24, 25]. The recent work of Monnier et al. [26] indicates
signiﬁcant diﬀerences between Type 1, insulin-treated, and
non-insulin-treated Type 2 diabetic patients in the activation
of oxidative stress and its association with insulin treatment
and glycemic variability. These diﬀerences may be partially
explained by the beneﬁcial eﬀect of insulin on the activation
of oxidative stress.
The objective of this study was to evaluate the eﬀects
of acute glycemia increase on microvascular reactivity and
endothelial function in Type 1 diabetic patients during
isoglycemic and hyperglycemic hyperinsulinemic clamp.
Possiblerelationshipbetweenrapidlyinducedhyperglycemia
andoxidativestresswasanalyzed.Therationaleforthisstudy
is a limited number of studies regarding glycemic variability
performed so far in Type 1 diabetic patients, unclear eﬀect
of single rapid glycemia increase in Type 1 diabetic patients,
and insuﬃcient understanding of diﬀerences in the eﬀect of
glycemic variability and insulin action on diabetic complica-
tions in patients with Type 1 and 2 diabetes who represent
two groups with diﬀerent metabolic and treatment proﬁles.
2.MaterialsandMethods
2.1. Patients. Sixteen patients with type 1 diabetes (mean age
51 ± 7 years, mean BMI 25.7 ± 3.7kg·m−2, mean diabetes
duration24±7years,andmeanHbA1C 7.8±0.9%according
to IFCC calibration) were studied. The diagnosis of diabetes
was based on its clinical appearance and undetectable C-
peptide levels (mean serum C-peptide < 0,05nmol/l). Only
patients without macro- and microvascular complications
were included in the study. All patients were treated with
continuous subcutaneous insulin infusion (CSII) using
insulinpumpinbasal-bolusregimen.Insulinusedwaseither
insulin analog lispro (n = 8) or aspart (n = 8). The mean
total daily basal dose was 24.9±9.1U, mean total daily bolus
dosewas21.8±5.7U,andthemeantotaldailydoseofinsulin
in studied subject was 47.0 ± 14U. Study was approved by
the local ethics committee and all subjects gave their written
informed consent before the experiment.
2.2. Clamp and the Control Test. Two tests were done in
this study: standard iso- and hyperglycemic clamp was
performed ﬁrst and then in 2–8 weeks the patients under-
went an isoglycemic control test. The control test without
insulin infusion and glucose increase was performed to
test for non-speciﬁc eﬀects of volume load (intravascular
volume expansion, hemodilution), so the patients served
also as the control group for themselves. Two of the sixteen
patients refused to participate in the control test. Clamp
test was performed by the method described previously
[27, 28] using intravenous human regular insulin infusion
rate0.001IU·kg−1·min−1. Insulin pump was stopped imme-
diately before the start of the test and started again after the
end of the test. Baseline glucose was 6.8 ± 2.7mmol·L−1.
Isoglycemic phase of the clamp was maintained for 3
hours (mean venous blood glucose 6.5 ± 1.9mmol·L−1)
and consequent hyperglycemic phase for next 3 hours
(mean venous blood glucose 12.0 ± 1.6mmol·L−1). Venous
blood glucose was measured in 5–10min intervals using
Super GL ambulance analyzer (Freital, Germany). Glucose
20% solution was infused at variable rate depending on
venous blood glucose level. Parameters of insulin sensitiv-
ity were calculated: glucose disposal rate (M), metabolic
clearance of glucose (MCRG), and insulin sensitivity index
(MCRG·I−1).
Duringthecontroltest,onlyintravenoussolutions(0.9%
natrium chloride solution and 20% glucose solution) of the
samevolumeasintheclamptestwereinfusedtoeachpatient
during 6 hours. Insulin pump was running at the patient’s
usual insulin basal rate, and glycemia was maintained at the
baseline value using variable rate of 20% glucose infusion.
Baseline venous blood glucose was 6.9 ± 2.2mmol·L−1 and
glycemia at the end of the test was 6.9 ±1.8mmol·L−1.
2.3. Biochemical Methods. Plasma insulin concentrations
were measured at the baseline, isoglycemic, and hyper-
glycemic phase of the clamp test and at the baseline
and the end of the control test. Insulin was measured
by radioimmunoassay kits (CIS Bio International, France),
with 5.6% intraassay and 7.2% interassay variabilities (CV)
in our laboratory. Other biochemical parameters were
measured at the baseline and at the end of the clamp
and the control test. Total serum cholesterol (TC), HDL-
cholesterol (HDL-C), and triglycerides (TG) were measured
byphotometricenzymaticmethodonanautomatedanalyzer
(COBAS Mira, Roche). LDL-cholesterol (LDL-C) was cal-
culated using the friedwald formula. Serum concentrations
of cell adhesion molecules E-selectin, P-selectin, intercellular
cell adhesion molecule 1 (ICAM-1), and vascular cell
adhesion molecule (VCAM) were measured with ELISA
kits manufactured by RD system Europe (Abingdon, UK).
The immunoassays had an intra-assay variability below
5% and an inter-assay variability below 8%. All samples
from the patients were measured in one assay to minimize
the eﬀect of variation. Plasma malonyl dialdehyde concen-
tration (MDA) was measured using ﬂuorimetric method
[29] with intra-assay variability below 3% and inter-assay
variability below 7% in our laboratory. Fibrinogen was
measured by the clauss method [30]o na na u t o m a t i c
analyzer.Experimental Diabetes Research 3
2.4. Laser Doppler Flowmetry. Skin microvascular reactivity
(MVR) was measured at the baseline and at the end of iso-
glycemic and hyperglycemic clamp phase and at the baseline
andattheendofthecontroltest.MVRwasmeasuredbylaser
Doppler ﬂowmetry using a PeriFlux PF 4001 Master laser
instrument and a PeriTemp 4001 Heater thermostatic unit
manufactured by Perimed (Sweden). Instrument settings
were as follows: time constant 0.02s, sampling frequency
32Hz, averaging from two samples. Measurements were
done at a room temperature of 22◦C. Postocclusive reactive
hyperemia (PORH) and thermal hyperemia (TH) tests
were used for the assessment of microvascular reactivity.
Measurement was done in two locations, ﬁngertip (ﬁ) and
forearm (fo). One standard probe (type 408, ﬁbre separation
0.25mm) was attached to the ﬁngertip of the third ﬁnger
of the nondominant upper extremity to record PORH only.
Second thermostatic probe (type 455, 23mm diameter,
ﬁber separation 0.25mm) was used for the recording of
PORH and TH on forearm. Optical ﬁbers in this probe are
integrated into the heating plate and thus the entire area
of tissue under the probe is heated. The probe was ﬁxed
with double-stick discs (3M, USA) to the skin of forearm
and its temperature was set to 32◦C for the purpose of
skin thermal stabilization during PORH and before TH. A
temperature of 44◦C was used during TH as the thermal
stimulus. Basal perfusion (PORHb) was measured for 2min
before the PORH test. The brachial artery was then occluded
by a sphygmomanometer cuﬀ inﬂated to a suprasystolic
pressure for 3 minutes and PORH was recorded after its
sudden release. Maximal perfusion during hyperemia was
recorded(PORHmax)aswellasthetimeneededforreaching
this maximal perfusion (PORHtmax). The velocity of the
perfusion increase (PORHmax/t) was calculated as the ratio
of (PORHmax-PORHb) and PORHtmax. Thermal hyper-
emia was measured 10 minutes after the PORH test. The
probe temperature was set to 44◦C, and parameters THmax,
THtmax, and THmax/t were recorded or calculated similarly
as those in the PORH test. Perfusion is given in arbitrary
perfusion units (PU). Perisoft for Windows 2.5 software was
usedforrecordingandevaluatingdata.Recordswereblinded
and the evaluation was performed by a single operator.
Statistical evaluation was performed by Statistica for
Windows software. Basic descriptive statistics were calcu-
lated for presented parameters. ANOVA, Student’s t-test or
Wilcoxon’s test, Mann-Whitney, and Kolmogorov-Smirnov
testswereusedforcomparingdata.Pearson’sandSpearman’s
correlations were used for analysis of relationships between
measured parameters. Data are expressed as mean ± S.D.
3. Results
Results of insulin sensitivity, lipid parameters, ﬁbrinogen,
oxidative stress, cell adhesion molecules, and microvascular
reactivity are presented in Table 1. Baseline values of all
v a r i a b l e sm e a s u r e di nt h ec l a m pa n dc o n t r o lt e s tw e r ec o m -
parable, no statistically signiﬁcant diﬀerences were found.
Serum total, HDL, and LDL-cholesterol decreased signif-
icantly in the hyperglycemic phase of the clamp compared
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Figure 1: Relationship between plasma ﬁbrinogen concentration
and maximal perfusion during thermal hyperemia (THmax) at the
baseline of the clamp (y = 167.44 − 21.07 × x; r =− 0.67; P =
0.009).
to the baseline, and similarly their concentration decreased
at the end of the control test. Serum triglycerides and MDA
concentrations did not change signiﬁcantly. Concentrations
of cell adhesion molecules (E- and P-selectin, ICAM-1 and
VCAM) decreased signiﬁcantly in the hyperglycemic phase
of the clamp as compared to the baseline, and similarly
they decreased during the control test (except for P-selectin
during the control test where only a trend to decrease could
be observed).
3.1. MVR at the Baseline of the Clamp. A negative rela-
tionship was found between ﬁbrinogen concentration and
maximal perfusion in thermal hyperemia and post-occlusive
reactive hyperemia at the ﬁngertip (r =− 0.67, P = 0.009,
Figure 1,a n d r =− 0.77, P<0.0005, Figure 2,r e s p . ) .
Another relationship was observed between ICAM-1 and
timetomaximumperfusionduringTH(r = 0.63,P = 0.016,
Figure 3).
3.2. MVR at the Isoglycemic Phase of the Clamp. In the fore-
arm, time to reach the maximum perfusion during PORH
was signiﬁcantly shorter and the velocity of perfusion in-
crease during PORH was higher in the isoglycemic clamp
phase compared to baseline (Table 1). Parameters of micro-
vascular reactivity measured at the ﬁngertip did not change
signiﬁcantly.
3.3. MVR at the Hyperglycemic Phase of the Clamp. At the
forearm, maximum perfusion and the velocity of perfusion
increase during PORH were signiﬁcantly higher in the
hyperglycemic phase of the clamp compared to baseline.
In thermal hyperemia, no changes of MVR were observed
in the clamp compared to baseline. However, time to
reach the maximum perfusion during TH was shorter and
velocity of perfusion increase during TH was higher at the
hyperglycemic phase compared to the isoglycemic phase.4 Experimental Diabetes Research
Table 1:Biochemicalparameters,parametersofinsulinsensitivityandmicrovascularreactivityduringisoglycemic(ISO)andhyperglycemic
(HYPER) hyperinsulinemic clamp and during the control test in Type 1 diabetic patients.
Clamp (n = 16) Control test (n = 14)
Baseline ISO Hyper Baseline End
Glucose (mmol·L−1)6 .8 ±2.76 .5 ±1.91 2 .0 ±1.66 .9 ±2.26 .9 ± 1.8
Insulin (mIU·L−1)5 5 ±39 155 ±54a 152 ±47a 74 ±55 65 ± 46
M( µmol/kg·min) — 30 ±10 57 ±26 — —
MCRG (mL/kg·min) — 5.0 ±2.34 .8 ±2.4— —
MCRG/L (mL/kg·min per mU/L ×100) — 3.5 ±1.63 .5 ±2.2— —
TC (mmol·L−1)4 .6 ±0.7—4 .3 ±0.6b 4.7 ±0.84 .3 ±0.8b
HDL-C (mmol·L−1)1 .3 ±0.4—1 .2 ±0.4b 1.3 ±0.41 .2 ±0.3b
LDL-C (mmol·L−1)2 .9 ±0.6—2 .7 ±0.5b 2.9 ±0.62 .7 ±0.6b
TG (mmol·L−1)0 .9 ±0.3—0 .8 ±0.21 .1 ±0.71 .0 ± 0.5
Fibrinogen (g· L−1)3 .4 ±0.9—3 .3 ±0.83 .4 ±1.03 .1 ±0.9b
MDA (µmol·L−1)1 .8 ±0.3—1 .8 ±0.21 .8 ±0.51 .7 ± 0.3
E-selectin (ng·mL−1)2 9 ±12 — 27 ±11a 29 ±15 28 ±14b
P-selectin (ng·mL−1) 132 ±50 — 93 ±34a 126 ±50 111 ±27
ICAM-1 (ng·mL−1) 251 ±48 — 215 ±41a 237 ±40 212 ±33b
VCAM (ng·mL−1) 812 ±183 — 673 ±117a 815 ±203 665 ±165a
PORHmax-ﬁ (PU) 224 ±88 255 ±112 234 ±99 212 ±92 199 ±60
PORHtmax-ﬁ (s) 24.7 ±22.11 5 .4 ±11.21 9 .1 ±12.21 9 .4 ±20.32 8 .3 ± 27.8
PORHmax/t-ﬁ (PU·s−1)8 .3 ±11.89 .3 ±12.64 .5 ±4.46 .7 ±7.71 3 .1 ± 20.5
PORHmax-fo (PU) 40 ±16 39 ±19 47 ±16b 32 ±12 35 ± 12
PORHtmax-fo (s) 13.5 ±5.16 .1 ±4.7a 10.4 ±8.41 1 .8 ±6.01 1 .3 ±9.0
PORHmax/t-fo (PU·s−1)2 .6 ±1.51 1 .2 ±14.9c 10.4 ±16.5c 2.7 ±2.43 .7 ± 3.0
THmax-fo (PU) 94 ±29 90 ±42 97 ±52 89 ±46 91 ± 45
THtmax-fo (s) 70 ±13 77 ±16 69 ±15x 70 ±16 64 ± 19
THmax/t-fo (PU·s−1)1 .3 ±0.51 .2 ±0.71 .4 ±0.8x 1.3 ±1.01 .7 ± 1.6
Statistical signiﬁcance of diﬀerences as compared to clamp and control test baseline values: aP<0.001, bP<0.01, cP<0.05, and xP<0.05 when comparing
isoglycemic and hyperglycemic phase.
M: glucose disposal rate, MCRG: metabolic clearance of glucose, MCRG/I: insulin sensitivity index, TC: total cholesterol, HDL-C: HDL-cholesterol, LDL-
C: LDL-cholesterol, TG: triglycerides, MDA: malonyl dialdehyde, ICAM-1: intercellular cell adhesion molecule 1, VCAM: vascular cell adhesion molecule,
PORHmax-ﬁ: maximal perfusion during postocclusive reactive hyperemia at ﬁngertip, PORHtmax-ﬁ: time to maximal perfusion during postocclusive
reactive hyperemia at ﬁngertip, PORHmax/t-ﬁ: velocity of perfusion increase during post-occlusive reactive hyperemia at ﬁngertip, PORHmax-fo: maximal
perfusion during post-occlusive reactive hyperemia in forearm, PORHtmax-fo: time maximal perfusion during post-occlusive reactive hyperemia in forearm,
PORHmax/t-fo:velocityofperfusionincreaseduringpost-occlusivereactivehyperemiainforearm,THmax-fo:maximalperfusionduringthermalhyperemia,
THtmax-fo: time to maximal perfusion during thermal hyperemia, and THmax/t-fo: velocity of perfusion increase during thermal hyperemia.
Parameters of microvascular reactivity measured at the
ﬁngertip did not change signiﬁcantly.
An inverse relationship was found between insulinemia
and the time to maximum perfusion during PORH at the
ﬁngertip (r =− 0.70, P = 0.007, Figure 4). Another inverse
relationship was observed between P-selectin and time to
maximum perfusion during PORH both at ﬁngertip and
forearm (r =− 0.57, P = 0.035, and r =− 0.60, P = 0.029,
Figures 5 and 6,r e s p . ) .
No relationship was observed between venous blood
glucose and MVR at any point during the clamp and the
control test. Similarly, no relationship was observed between
parameters of insulin sensitivity and MVR.
3.4. MVR in the Control Test. During the control test, no
changes in MVR were observed at all, both for PORH and
TH tests.
4. Discussion
In this study, we did not prove the hypothesis that rapidly
induced hyperglycemia impairs microvascular reactivity in
patients with Type 1 diabetes. No relationship was observed
between venous glucose and microvascular reactivity during
the hyperinsulinemic isoglycemic and hyperglycemic clamp.
This is in accordance with the ﬁndings of Oomen et al. [22]
in a similar study.
Dynamic parameters of MVR indicated faster microvas-
cular vasodilation in the isoglycemic phase during which
only hyperinsulinemia was present. Faster microvascular
vasodilation persisted also in the hyperglycemic phase and
was not abolished by the rapid glycemia increase. In the
hyperglycemic phase, insulinemia was associated with the
time needed to reach the maximum perfusion during PORH
at the ﬁngertip resulting in faster onset of the maximum
perfusion in patients with higher insulin concentration. OurExperimental Diabetes Research 5
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Figure 2: Relationship between plasma ﬁbrinogen concentration
and maximal perfusion during postocclusive reactive hyperemia
at the ﬁngertip (PORHmax-ﬁ) at the baseline of the clamp (y =
482.04 −75.47 ×x; r =− 0.77; P = 0.0005).
160 180 200 220 240 260 280 300 320 340 360
40
50
60
70
80
90
100
T
H
t
m
a
x
 
(
s
)
ICAM-1 (ng·mL−1)
Figure 3: Relationship between serum intercellular cell adhesion
molecule-1 (ICAM-1) and the time to maximal perfusion during
thermal hyperemia (THtmax) at the baseline of the clamp (y =
29.34+ 0.16 ×x; r =− 0.63; P = 0.016).
results suggest that the vasodilation eﬀect of insulin may
play a signiﬁcant role in the regulation of microvascular
perfusion in patients with diabetes. The reason why we
did not observe signiﬁcant correlation between insulinemia
and parameters of MVR also in forearm resides possibly in
capillary bed diﬀerences. Capillary bed of the ﬁngertip is
diﬀerent from forearm [31]. It is more dense and contains
multiple shunts. It is considered rather functional than
simply nutritional. The basal perfusion is usually several
times higher in ﬁngertips than in other skin locations. It
may be therefore easier to detect the vasodilation related to
insulin in ﬁngertip than in forearm where we observed only
nonsigniﬁcant correlations between insulinemia and MVR
during the clamp.
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Figure 4: Relationship between plasma insulin concentration and
the time to maximal perfusion during postocclusive hyperemia at
the ﬁngertip (PORHtmax-ﬁ) in the hyperglycemic phase of the
clamp (y = 48.03 − 0.20 ×x; r =− 0.70; P = 0.007).
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Figure 5: Relationship between serum P-selectin concentration
and the time to maximal perfusion during postocclusive reactive
hyperemia at the ﬁngertip (PORHtmax-ﬁ) in the hyperglycemic
phase of the clamp (y = 38.83 −0.20 ×x; r =− 0.57; P = 0.035).
Chronic hyperglycemia induces biochemical abnormali-
ties in many systems including hemocoagulation/ﬁbrinolysis
pathways and cell adhesion molecules and induce oxidative
stress [32–35]. However, we did not observe any alteration
in these systems following the clamp, probably a single
and relatively short clamp test was not enough to induce
signiﬁcant changes [36]. Signiﬁcant decline in cell adhesion
molecules concentration during the clamp (as well as in lipid
parameters) was probably nonspeciﬁc as it was reproduced
in the control test as well. It was probably caused by
hemodilution during relatively high intravenous volume
load. The control test was included in the study protocol
design to exclude the inﬂuence of any non-speciﬁc eﬀects,
especially for the eﬀect of intravenous volume load. Infusion6 Experimental Diabetes Research
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Figure 6: Relationship between serum P-selectin concentration
and the time to maximal perfusion during postocclusive reactive
hyperemia in the forearm (PORHtmax-fo) in the hyperglycemic
phase of the clamp (y = 24.21 −0.14 × x; r =− 0.60; P = 0.029).
of intravenous ﬂuids in larger quantities is necessarily
connectedwithclamptechniques.Inthecontroltest,wehave
not observed any changes in microvascular reactivity in the
link with increased intravascular volume.
Hyperglycemia induces platelet aggregation and activates
procoagulation factors not only in Type 2 diabetic patients
[37], but also in healthy subjects [38, 39], and coagulation
is closely related to endothelial function. This is in an
accordance with our observation of a negative relationship
between plasma ﬁbrinogen concentration and MVR at the
baselineoftheclamp.Surprisingly,higherlevelsofP-selectin,
a marker of platelet activation and procoagulation [40], were
associated with faster vasodilation in PORH both at ﬁngertip
and in the forearm at the end of the clamp test. Unfortu-
nately, it is not possible to distinguish whether this observa-
tion is related to hyperglycemia, hyperinsulinemia, or both.
The inﬂuence of insulin on the development of vascular
c o m p l i c a t i o n si nd i a b e t e si ss t i l lu n c l e a r .I n s u l i nc o n c e n -
tration varies in diﬀerent types of diabetes (depending on
the type and progress of metabolic disorder) and is often
massively modiﬁed by antidiabetic treatment. This further
complicates the understanding of relationship between
insulin levels and vascular complications. Insulin levels
a r eu s u a l l yh i g h e ri ne a r l ys t a g e so fT y p e2d i a b e t e s( o r
even in prediabetes) and decline consequently [41]. Insulin
deﬁciency develops in a large portion of Type 2 diabetic
patients due to the apoptosis of B cells [42]. As an example of
a study designed to eliminate the eﬀect of insulin, Ceriello et
al.describedamoredeleteriouseﬀectofﬂuctuatingglycemia
than that of sustained hyperglycemia on oxidative stress
and endothelial function in Type 2 diabetic patients whose
insulin secretion was completely blocked by somatostatin
during the experiments [17]. On the other hand, Monnier
et al. described similar ﬁndings in the presence of insulin in
a clinical setting using continual glucose monitoring system
in otherwise normally treated Type 2 diabetic patients [18].
Further data published recently by Monnier et al. indicate
thattheactivationoftheoxidativestressasassessedfrom24h
urinary excretion rates of 8-isoPGF2alpha is within the nor-
mal range in all diabetic patients treated with insulin (both
Type 1 and Type 2) whilst this parameter is signiﬁcantly ele-
vatedinthosepatientswhouseoralhypoglycemicagentsand
no insulin treatment [26]. In the same study, an association
between the activation of oxidative stress and glycemic vari-
ability was found only in the group of non-insulin-treated
Type 2 diabetic patients. Such results are in agreement with
those found in the present work and seem to indicate that
insulin per se exerts beneﬁcial eﬀect on several factors that
mayplayaroleinthedevelopmentofdiabeticcomplications.
In Type 1 diabetic patients, diabetes is manifested
when decline in B cell leads to clinically signiﬁcant insulin
deﬁciency. Following the initiation of insulin substitution
therapy in these patients, they can have hypo-, normo- or
even hyperinsulinemia depending on the dose of injected or
infused insulin [43]. Concentration of glucose ﬂuctuates in
these patients (as well as in insulin-treated Type 2 diabetic
patient) according to insulin dose. When glycemic variability
is considered a risk factor for the development of vascular
complications by some authors, a question shall be raised if
even insulin variability cannot participate as well. In studies
testing vascular function in diabetic patients, it may be
therefore very useful to measure and mention the insulin
levels despite some technical diﬃculties and always check
for possible relationship between insulin concentration and
vascular function.
5. Conclusion
In the isoglycemic and hyperglycemic hyperinsulinemic
clamp, we have not observed any impairment of microvas-
cular reactivity following fast glycemia increase in patients
with Type 1 diabetes. Our results suggest that insulin may
play a signiﬁcant role in the regulation of microvascular
perfusion in patients with diabetes through its vasodilation
eﬀect. We have also shown the importance of the control
test with intravenous volume load in studies using clamp
techniques. Further research is necessary to clarify the eﬀect
of glucose and insulin ﬂuctuation on vascular function and
development of diabetic complications.
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